PharmaCyte Biotech (PMCB) director corrects erroneous, cancelled option grant
Filing Impact
Filing Sentiment
Form Type
4/A
Rhea-AI Filing Summary
WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Wayne Remell Walker reported an administrative correction to a prior stock option grant. The footnote explains that the grant was made in error and has been cancelled, leaving 0.0000 derivative securities from this grant and no common stock bought or sold.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
WALKER WAYNE REMELL
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Other | Stock Option (Right to Buy) | 0 | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Derivative securities after correction: 0.0000
Transaction date: 2026-03-31
Net common shares traded: 0
3 metrics
Derivative securities after correction
0.0000
Stock Option (Right to Buy) position after erroneous grant was cancelled
Transaction date
2026-03-31
Date associated with the corrected derivative transaction entry
Net common shares traded
0
No PMCB common stock purchases or sales reported in this amendment
Key Terms
Stock Option (Right to Buy), Other acquisition or disposition, derivative securities
3 terms
Stock Option (Right to Buy) financial
"The security title is reported as "Stock Option (Right to Buy)"."
Other acquisition or disposition financial
"The transaction code description is "Other acquisition or disposition"."
derivative securities financial
"The filing classifies the option as derivative securities with 0.0000 remaining."
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did PharmaCyte Biotech (PMCB) director Wayne Remell Walker report in this Form 4/A?
He reported an administrative correction to a previously reported stock option grant. A footnote states the grant was made in error and has been cancelled, with no common shares purchased or sold in connection with this amendment.
Did Wayne Remell Walker buy or sell PMCB common stock in this insider filing?
No common stock was bought or sold. The only entry is a derivative “Stock Option (Right to Buy)” line showing 0.0000 securities after cancellation of an erroneously reported grant, so there is no reported trading in PMCB shares.
What does the footnote in Wayne Remell Walker’s PMCB Form 4/A say?
The footnote states that “The reported grant was made in error and has been cancelled.” This means the option award previously reported is no longer outstanding, and the corrected line reflects that cancellation with zero derivative securities remaining.
How many PharmaCyte Biotech derivative securities does Wayne Remell Walker show after this correction?
For the reported “Stock Option (Right to Buy)” entry, the post-transaction amount is 0.0000 derivative securities. This aligns with the footnote that the grant was made in error and cancelled, so no options from that grant remain outstanding.
What is the transaction date of the corrected PMCB option entry for Wayne Remell Walker?
The corrected derivative entry uses a transaction date of 2026-03-31. On that date, the report characterizes the event as an “Other acquisition or disposition,” tied to cancelling an erroneously granted stock option with no net share activity.